BiotechTube
Home/Immutep/Deanne Miller
DM

Deanne Miller

Chief Operating Officer, General Counsel & Company Secretary

Immutep

Therapeutic Areas

OncologyAutoimmune Diseases

Immutep Pipeline

DrugIndicationPhase
Eftilagimod alfa (efti)1st & 2nd line Non-Small Cell Lung Cancer (NSCLC)Phase 2/3
IMP761Autoimmune DiseasesPhase 1 (planned)
IMP731Ulcerative ColitisPhase 2
LAG525 (ieramilimab)Various cancers (Novartis partnership)Multiple Phases
Novel Small Molecule LAG-3 InhibitorOncologyEarly Research

Leadership Team at Immutep

MV
Marc Voigt
Chief Executive Officer & Executive Director
FT
Frédéric Triebel
Chief Scientific Officer & Executive Director
CM
Christian Mueller
Chief Development Officer
View full Immutep profile